Here, we have assessed the impact of de novo and inherited
rare CNV in 2,446 ASD individuals and their
parents from the Autism Genome Project (AGP), along
with 2,640 unrelated controls, by applying a series of
approaches to characterize candidate ASD-associated genes
disrupted by CNVs and to identify the biological relationships
and common pathways they share. Using evidence
from multiple sources, we were able to directly implicate
numerous dosage-sensitive genes as risk factors and provide
insights into different but related mechanisms underlying
ASD.